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The Effect of  Psychiatric Comorbidities on Headache-Related 
Disability in Migraine: Results From the Chronic Migraine 
Epidemiology and Outcomes (CaMEO) Study
Richard B. Lipton, MD; Elizabeth K. Seng, PhD; Min Kyung Chu, MD, PhD; Michael L. Reed, PhD;  
Kristina M. Fanning, PhD; Aubrey Manack Adams, PhD; Dawn C. Buse, PhD
Objective.—To examine the influences of depression and anxiety on headache-related disability in people with episodic 
migraine or chronic migraine.
Background.—Depression and anxiety are common comorbidities in people with migraine, especially among those with 
chronic migraine.
Methods.—This cross-sectional analysis of data from the longitudinal, internet-based Chronic Migraine Epidemiology and 
Outcomes Study assessed sociodemographic and headache features, and headache-related disability (Migraine Disability Assessment 
Scale). Four groups were defined based on scores from validated screeners for depression (9-item Patient Health Questionnaire) 
and anxiety (7-item Generalized Anxiety Disorder Scale): depression alone, anxiety alone, both, or neither.
Results.—Respondents (N  =  16,788) were predominantly women (74.4% [12,494/16,788]) and white (84.0% [14,044/16,788]); 
mean age was 41 years. Depression was more likely in persons with chronic migraine vs episodic migraine (56.6% [836/1476] 
vs 30.0% [4589/15,312]; P  <  .001), as were anxiety (48.4% [715/1476] vs 28.1% 4307/15,312]; P  <  .001) and coexisting depres-
sion and anxiety (42.0% [620/1476] vs 20.8% [3192/15,312]; P  <  .001). After controlling for headache frequency and other 
covariates, depression alone, and anxiety alone were associated with 56.0% (rate ratio [RR], 1.56; 95% confidence interval [CI], 
1.46-1.66) and 39.0% (RR, 1.39; 95% CI, 1.30-1.50) increased risks of moderate/severe migraine-related disability (both P < .001), 
respectively; the combination had an even greater effect on risk of moderate/severe disability (79.0% increase; RR, 1.79; 95% 
CI, 1.71-1.87; P  <  .001).
Conclusions.—Depression alone and anxiety alone are associated with greater headache-related disability after controlling 
for sociodemographic and headache features. Coexisting depression and anxiety are more strongly associated with disability than 
either comorbidity in isolation. Interventions targeting depression and anxiety as well as migraine itself may improve headache-
related disability in people with migraine.
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INTRODUCTION
Migraine, a chronic and debilitating neurologic 
disease, is characterized by episodic attacks of head-
ache pain and other associated symptoms.1,2 Globally, 
migraine affects approximately 1 in 7 individuals with 
a prevalence of more than 1 billion people. It is sec-
ond only to lower back pain as a leading cause of years 
lived with disability.3
Depression and anxiety are comorbid with mi-
graine and with each other.4-8 Although estimates vary, 
in population-based samples of people with migraine, 
up to 47% have comorbid depression, and up to 58% 
have comorbid anxiety.7,9 Both depression and anxi-
ety are more common among people with chronic mi-
graine (CM; defined as at least 15 headache days per 
month over the preceding 3 months with migraine fea-
tures present on at least 8 days per month) than in peo-
ple with episodic migraine (EM).9-11 Furthermore, the 
presence of comorbid depression in people with EM 
has been shown to predict risk of progression to CM 
the following year.12 Relationships between comorbid 
depression and migraine are bidirectional.4,7,9,13 This 
is consistent with emerging evidence of genetic links 
between migraine, depression, and anxiety.14
In general, the presence of both migraine and 
psychiatric disorders such as anxiety and depression 
portends worsened symptomatology for each condi-
tion.5,12 Comorbid depression and anxiety in people 
with migraine are associated with greater health ex-
penditures and medication use than in people with 
migraine without these comorbidities.9,15 Psychiatric 
comorbidities in migraine can diminish quality of life 
(QoL) and increase the burden and disability associ-
ated with migraine.16-18 Comorbid depression and/or 
anxiety can also affect medication selection, response 
to preventive medication, behavioral migraine treat-
ment, and adherence to migraine treatment plans.9,19,20
The separate and joint associations of depres-
sion and anxiety with disability in persons with mi-
graine have not been evaluated; further, analyses of 
relationships between depression and anxiety and 
migraine disability have typically not been adjusted for 
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headache days. The Chronic Migraine Epidemiology 
and Outcomes (CaMEO) Study was designed to char-
acterize self-reported headache symptoms, severity, 
disability, comorbidities, and other variables in a rep-
resentative U.S. sample of people with migraine.21 This 
subanalysis of the CaMEO Study sample was under-
taken to investigate and compare the separate and joint 
influences of depression and anxiety on headache- 
related disability in people with migraine, to compare 
these effects in CM and EM, to identify unmet needs, 
and to provide relevant clinical information to guide 
treatment planning. We hypothesized that at increas-
ing levels of monthly headache-day frequency, persons 
with depression or anxiety would have elevated lev-
els of headache-related disability and that the effects 
would be greater in persons with coexisting depression 
and anxiety.
METHODS
Study Design.—The CaMEO Study methodology 
has been detailed previously.21 This longitudinal 
Internet-based study with cross-sectional modules 
(ClinicalTrials.gov identifier: NCT01648530) as-
sessed headache symptoms, severity, frequency, and 
disability; and migraine-related consulting practic-
es, health-care utilization, medication use, comor-
bid health conditions, and family related burden as-
sociated with headache over the course of  1 year.21 
Recruiting and screening occurred between Septem-
ber and October 2012. Participants were recruited 
from an Internet research panel (Dynata [formerly 
Research Now], Plano, TX, USA) using sampling 
quotas based on the U.S. Census. The CaMEO Study 
was approved by the Albert Einstein College of  Med-
icine Institutional Review Board. Written informed 
consent was not required for survey respondents; 
completion of  the survey was considered consent 
to participate. All study authors had full access to 
all data.
Study Participants.—Adults were eligible for in-
clusion in the study if  they volunteered to participate 
(Fig. 1),22 passed quality control measures, and met 
modified symptom criteria for migraine from the Inter-
national Classification of Headache Disorders, third edi-
tion (ICHD-3) using the validated American Migraine 
Study/American Migraine Prevalence and Prevention 
(AMPP) study migraine screener.21,23 Respondents 
with CM were defined as those with at least 15 head-
ache days per month (Silberstein-Lipton criteria24), 
calculated as the average of monthly headache days 
over the preceding 3 months.21
Headache-Related Disability.—The Migraine Dis-
ability Assessment Scale (MIDAS) is a 7-item mea-
sure of headache-related disability over the previous 
3 months.25 The 5 scored items assess the number of 
days that migraine prevented (absenteeism) or limited 
(presenteeism) work and nonwork activities. The to-
tal score sums the number of days for these 5 items, 
with higher scores indicating greater disability classi-
fied into 4 severity grades: 0 to 5: Grade I (minimal or 
infrequent disability); 6 to 10: Grade II (mild or infre-
quent disability); 11 to 20: Grade III (moderate disabil-
ity); and ≥21: Grade IV (severe disability).
Depression.—Depression was assessed using the 
9-item Patient Health Questionnaire (PHQ-9),26 a 
validated measure of  major depressive disorder based 
on Diagnostic and Statistical Manual of Mental Dis-
orders, fourth edition (DSM-IV) criteria.27 This as-
sessment tool sums 9 questions rated from 0 (not at 
all) to 3 (nearly every day) to provide a total possible 
score of  27 to determine depression over the pre-
ceding 2 weeks. The validated sum scoring method 
advised that PHQ-9 total scores can be used to cate-
gorize depression as none to minimal (0-4), mild (5-
9), moderate (10-14), moderately severe (15-19), and 
severe (20-27).26 For this analysis, respondents with 
a PHQ-9 total score ≥10 were classified as screening 
positive for depression.
Anxiety.—Anxiety was assessed using the 7-item 
Generalized Anxiety Disorder Scale (GAD-7). This 
validated scale sums 7 questions based on DSM-IV cri-
teria27 rated from 0 (not at all) to 3 (nearly every day) 
for the preceding 2 weeks, resulting in a total score be-
tween 0 and 21. The validated scoring method advised 
that GAD-7 scores of 10 to 14 indicate moderate anx-
iety, and scores ≥15 indicate severe anxiety.28 For this 
analysis, respondents with a GAD-7 total score ≥10 
were classified as screening positive for anxiety.
Combined Anxiety/Depression Variable.—Four psy-
chiatric subgroups of participants were defined based 
on the presence and/or absence of depression and 
anxiety using responses to screeners for symptoms of 
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depression (PHQ-9 score ≥10) and anxiety (GAD-7 
score ≥10) as follows: Neither depression nor anxiety, 
depression alone, anxiety alone, and both depres-
sion and anxiety.
Other Assessments.—The influences of depres-
sion and anxiety were assessed both separately and 
jointly on the following factors: sociodemographic and 
headache features, migraine symptom severity com-
posite sum score (Migraine Symptom Severity Score 
[MSSS]), and cutaneous allodynia (based on the 12-
item Allodynia Symptom Checklist [ASC-12]). The 
MSSS, a composite index, is based on the frequency of 
7 key migraine features, including unilateral pain, pul-
satile pain, moderate or severe pain intensity, routine 
activities worsening pain, nausea, photophobia, and 
phonophobia.29 Responses for each feature range from 
1 to 4 (lower to higher frequency), yielding an overall 
sum score of 7 to 28. For the ASC-12 (scoring range: 
0 = not applicable/never/rarely; 1 = less than half  the 
time; 2 = half  the time or more), scores of at least 3 are 
indicative of the presence of allodynia.30
Statistical Analysis.—Descriptive data are pro-
vided for the total sample, comparing episodic and 
chronic migraine groups and across the 4 anxiety/
depression symptom groups. Ratio scale variables 
(age, body mass index [BMI], monthly headache 
days) and interval scale variable (MSSS) are de-
scribed by means and standard deviations. Nominal 
scale variables (gender, race) and ordinal scale vari-
ables (depression, anxiety, allodynia, MIDAS grade 
III or IV, income, monthly headache day catego-
ries) are described by percentages.
Fig 1.—Respondent flow diagram. About 22,365 respondents abandoned the survey, were over quota, or had invalid (unusable) data 
and were removed during data cleaning. Met inclusion criteria: agreed to participate, screened positive for modified International 
Classification of Headache Disorders, third edition, migraine criteria, were ≥18 years of age, and had ≥1 headache in the previous 12 
months. Note: There was 1 person with missing data for the anxiety and depression measures, so the sample size for this study differs 
by n  =  1 from the total CaMEO baseline sample. Chronic Migraine Epidemiology and Outcomes (CaMEO); Chronic Migraine 
(CM); episodic migraine (EM). [Color figure can be viewed at wileyonlinelibrary.com]
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T-test for independent groups (for EM vs CM com-
parisons) and one-way analysis of variance (ANOVA; 
for comparisons across the 4 psychiatric subgroups) 
were used to test for differences across interval or ratio 
scale variables, and chi-squared was used to test differ-
ences for nominal or ordinal scale variables. All tests 
were 2 sided with a significance level set at .05.
MIDAS was modeled using negative binomial re-
gression, which was applied to account for the skewed 
count distribution of MIDAS scores. The 4-group anx-
iety and depression variable was the primary indepen-
dent variable of interest. Additional covariates included 
age, gender, income, race, allodynia, BMI, monthly 
headache-day frequency, and MSSS. Results were re-
ported as rate ratios (RRs) and 95% CIs. The adjusted 
negative binomial regression model also was programed 
to generate predicted MIDAS scores, which were then 
used in a plot against monthly headache-day frequency. 
All analyses were undertaken using SPSS Statistics, ver-
sion 22.0 (IBM Corp.; Armonk, NY, USA).
RESULTS
Study Respondent Demographics and Disposition.— 
Full details of the study respondents have been pub-
lished previously.21 The sociodemographic character-
istics of the 16,788 respondents with migraine who 
qualified for inclusion are provided for the entire popu-
lation in Table 1 and for the entire population stratified 
by the presence or absence of depression or anxiety 
in Table 2. There was 1 respondent with missing data 
on the depression and anxiety measures; therefore, this 
study sample differs by n = 1 from the total CaMEO 
baseline sample. Respondents were predominantly 
women (74.4%) and white (84.0%) with a mean BMI of 
28.7 kg/m2 (overweight). At baseline, respondents had 
a mean monthly headache-day frequency of 5.0 and 
mean MSSS score of 22.4. Among all respondents, 
6539 (39.0%) had Grade III/IV (moderate to severe) 
MIDAS scores, and 5820 (45.4%) had cutaneous allo-
dynia (ASC-12 ≥3; Table 1). There were significant dif-
ferences across the anxiety and depression subgroups 
in all of the sociodemographic characteristics evaluat-
ed, except race (Table 2).
Depression criteria were met by 5425 (32.3%) re-
spondents. Anxiety criteria were met by 5022 (29.9%) 
respondents. Of all respondents, 1613 (9.6%) had 
depression only, 1210 (7.2%) had anxiety only, and 
3812 (22.7%) had both depression and anxiety; 10,153 
(60.5%) respondents had neither depression nor anxi-
ety (Table 1).
Table 1.—Baseline Demographics, Headache 





Age, years, mean (SD) 41 (14)











BMI, kg/m2, mean (SD) 28.7 (7.6)
Cutaneous allodynia, ASC-12 ≥3,¶ n (%) 5820 (45.4)
MSSS, mean (SD) 22.4 (3.2)
MIDAS score grade III/IV, n (%) 6539 (39.0)
Monthly headache-day frequency
Days/month, mean (SD) 5.0 (6.0)
Category, n (%)
0-4 days/month 11,159 (66.5)
5-9 days/month 2904 (17.3)
10-14 days/month 1249 (7.4)
≥15 days/month 1476 (8.8)
Depression† 5425 (32.3)
Anxiety‡ 5022 (29.9)
Psychiatric subgroups, n (%)
Depression only 1613 (9.6)
Anxiety only 1210 (7.2)
Depression and anxiety 3812 (22.7)
Neither depression nor anxiety 10,153 (60.5)
†Depression was defined as 9-item Patient Health Questionnaire 
score ≥10.
‡Anxiety was defined as 7-item Generalized Anxiety Disorder 
Scale score ≥10.
§Subsample that completed Endophenotype Module and who 
were included in the final model. Note: There was one person 
with missing data for the anxiety and depression measures, so the 
sample size for this study differs by n = 1 from the total CaMEO 
baseline sample.
¶Results were not provided by all respondents; percentages are 
reported as the percentage of respondents for each data point.
ASC-12 = 12-item Allodynia Symptom Checklist; BMI = body 
mass index; CM = chronic migraine; EM = episodic migraine; 
MIDAS = Migraine Disability Assessment Scale; MSSS = 
































































































































































































































































































































































































































































































































































































































































































































































































Headache Characteristics: EM vs CM.—There were 
15,312 (91.2%) respondents characterized as having 
EM and 1476 (8.8%) characterized as having CM. By 
definition, respondents with CM had a greater num-
ber of headache days per month than did those with 
EM (21.0 vs 3.5 days/month, P <  .001; Table 3). Re-
spondents with CM compared with EM, respective-
ly, were also more likely to have cutaneous allodynia 
(ASC-12 ≥3, 697 [62.7%] vs 5123 [43.8%]; P  <  .001), 
to experience significantly greater headache-related 
disability (MIDAS Grade III/IV, 1187 [80.4%] vs 5352 
[35.0%]; P < .001), and to have a higher mean symptom 
severity as assessed by the MSSS (23.8 vs 22.2; P < .01; 
Table 3).
Depression and Anxiety Status: EM vs CM.— 
Clinically relevant levels of depression, defined by a 
PHQ-9 score ≥10, were more likely to be present in 
respondents with CM than EM (n  =  836 [56.6%] vs 
n  =  4589 [30.0%]; P  <  .001). Clinically relevant lev-
els of anxiety, defined by a GAD-7 score ≥10, were 
more likely to be present in respondents with CM than 
EM (n = 715 [48.4%] vs n = 4307 [28.1%]; P < .001). 
Respondents with CM compared with EM were more 
likely to have met criteria for depression only (n = 216 
[14.6%] vs n = 1397 [9.1%]) or for depression and anx-
iety (n = 620 [42.0%] vs n = 3192 [20.8%]), and respon-
dents with EM compared with CM were more likely to 
have met criteria for anxiety only (n = 1115 [7.3%] vs 
n = 95 [6.4%]) or having neither depression nor anx-
iety (n = 9608 [62.7%] vs n = 545 [36.9%]; P <  .001; 
Table 3).
Relationship of MIDAS Score With Psychiatric 
Comorbidities.—MIDAS scores increased in the pres-
ence of the assessed psychiatric comorbidities (Fig. 2). 
The proportion of respondents with a Grade III/IV 
MIDAS score reflecting moderate/severe disability 
among respondents with neither depression nor anx-
iety was 28.2%. Rates of moderate/severe disability 
were higher among respondents with anxiety alone 
(43.3%), depression alone (51.7%), and those with 
both depression and anxiety (61.0%). A range of fac-
tors was associated with the MIDAS scores in the 
moderate or severe disability range (Fig. 3), including 
monthly headache-day frequency, MSSS, cutaneous 
allodynia, depression alone, anxiety alone, and both 
depression and anxiety. After controlling for head-
Table 3.—Headache and Psychiatric Comorbidity Characteristics at Baseline by EM and CM
Characteristic EM (n = 15,312) CM (n = 1476) P Value
Cutaneous allodynia, ASC-12 ≥3,† n (%) 5123 (43.8) 697 (62.7) <.001
MSSS, mean (SD) 22.2 (3.2) 23.8 (3.0) <.01
MIDAS score grade III/IV, n (%) 5352 (35.0) 1187 (80.4) <.001
Monthly headache-day frequency
Days/month, mean (SD) 3.5 (3.2) 21.0 (4.9) <.001
Category, n (%)
0-4 days/month 11,159 (72.9) 0 <.001
5-9 days/month 2904 (19.0) 0
10-14 days/month 1249 (8.2) 0
≥15 days/month 0 1476 (100)
Depression‡ 4589 (30.0) 836 (56.6) <.001
Anxiety§ 4307 (28.1) 715 (48.4) <.001
Psychiatric subgroups <.001
Depression only 1397 (9.1) 216 (14.6)
Anxiety only 1115 (7.3) 95 (6.4)
Depression and anxiety 3192 (20.8) 620 (42.0)
Neither depression nor anxiety 9608 (62.7) 545 (36.9)
†Results were not available for all respondents; percentages are reported as the percentage of respondents for each data point.
‡Depression was defined as 9-item Patient Health Questionnaire score ≥10.
§Anxiety was defined as 7-item Generalized Anxiety Disorder Scale score ≥10.
ASC-12 = 12-item Allodynia Symptom Checklist; CM = chronic migraine; EM = episodic migraine; MIDAS = Migraine Disability 
Assessment Scale; MSSS = Migraine Symptom Severity Score.
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ache-day frequency and other covariates, depression 
alone, and anxiety alone increased the risk of dis-
ability caused by migraine by 56.0% (RR: 1.56, 95% 
CI: 1.46,1.66; P < .001) and 39% (RR: 1.39, 95% CI: 
1.30,1.50; P < .001), respectively, and together had an 
even greater effect (79.0% increase in risk; RR: 1.79, 
95% CI: 1.71,1.87; P  <  .001; Fig. 3). Increasing age, 
being male, and being white were all protective against 
increases in MIDAS, as evidenced by RRs <1 with all 
covariates included in the model (Table S1 in Supple-
mental Data).
Relationship of MIDAS Score With Headache-Day 
Frequency.—Predicted MIDAS scores by monthly 
headache-day frequency ranged from 5 to 60 for those 
with 0 to 14 headache days per month, and from 27 to 
282 for those with 15 to 30 headache days per month. 
Among the psychiatric symptom subgroups, the great-
est risk of headache-related disability at nearly any 
Fig 2.—Percentage of respondents with moderate or severe disability as indicated by a Migraine Disability Assessment Scale Grade 
of III or IV, stratified by presence of anxiety and/or depression. Migraine Disability Assessment Scale (MIDAS). [Color figure can 
be viewed at wileyonlinelibrary.com]
Fig 3.—Predictors of headache-related disability (MIDAS), as indicated by RRs and P values. The model was run adjusting for sex, 
age (in 10-year increments), race (white vs nonwhite), BMI, annual household income, monthly headache-day frequency, MSSS score 
(1-point increments), and cutaneous allodynia. Sex, age in 10-year increments, white race, BMI, monthly headache-day frequency, 
MSSS score (1-point increments), and cutaneous allodynia were all significant. Income brackets were also included in the model 
and were significant for $50,000 to $74,999 and ≥$75,000. The reference group had neither anxiety nor depression. Body mass index 
(BMI); Migraine Disability Assessment Scale (MIDAS); Migraine Symptom Severity Score (MSSS); rate ratio (RR). [Color figure 
can be viewed at wileyonlinelibrary.com]
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given headache-day frequency was observed among 
respondents with both depression and anxiety, while the 
lowest risk of disability was observed for those with 
neither condition (Fig. 4).
DISCUSSION
Prior research has demonstrated robust associa-
tions among depression, anxiety, and migraine.6,18,31 
The present analysis expands on the existing litera-
ture by demonstrating that depression and anxiety are 
separately and jointly associated with headache-related 
disability in persons with migraine. Using validated 
clinical cutoffs on the PHQ-9 and GAD-7 scales, this 
subanalysis of the CaMEO study population revealed 
that clinically relevant depression and anxiety were 
present in a large proportion of respondents with mi-
graine. In agreement with prior studies, a significantly 
larger proportion of respondents with CM than EM re-
ported clinically relevant depression and anxiety.11,32-34
In our study, the presence of clinically relevant 
depression and anxiety individually was significantly 
associated with moderate/severe headache-related 
disability as measured by MIDAS. Depression and 
anxiety together showed a higher association with dis-
ability than either depression alone or anxiety alone. 
The lower bound of the 95% CI for the rate of mod-
erate/severe disability in the group with depression 
and anxiety exceeded the upper bound of the 95% CI 
for the group with either depression alone or anxiety 
alone. These results support a combined influence of 
depression and anxiety on headache-related disability. 
Comorbid conditions in general have been shown to 
explain a large proportion of the disability associated 
with migraine.35 A nationally representative, face-to-
face household survey of 5692 U.S. adults showed 
that 83% of participants with migraine had some form 
of comorbidity (eg, mental disorders [53%], chronic 
pain disorders [58%], and physical diseases [47%]).35 
Results of the study showed that after adjustment for 
sociodemographic characteristics, comorbid condi-
tions explained approximately 65% of role disability 
(days with impaired role functioning per the World 
Health Organization Disability Assessment Schedule) 
associated with migraine.35 The individual contribu-
tions of anxiety and depression to migraine and, fur-
ther, to headache-related disability remain to be fully 
understood.
Prior literature is broadly compatible with our find-
ings, although there are some discrepancies. Most stud-
ies have demonstrated migraine’s association with both 
depression and anxiety, albeit with some variations 
in rates.6,7,10,16 In contrast to findings that depressive 
symptoms are more common than anxiety symptoms, 
other studies have found that anxiety is more com-
mon than depression in people with migraine.7,36 The 
FRAMIG 3 Study, a nationwide population-based 
postal survey carried out in France (n = 1179 respon-
dents with migraine), used the Hospital Anxiety and 
Fig 4.—Predicted MIDAS score by monthly headache days for each psychiatric subgroup. Note that for 0-14 monthly headache days, 
the predicted mean MIDAS scores on the Y-axis range from 0 to 60, whereas for 15-30 monthly headache days, they range from 0 to 
300. Migraine Disability Assessment Scale (MIDASs). [Color figure can be viewed at wileyonlinelibrary.com]
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Depression Scale to assess anxiety and depression and 
reported that 28% of respondents with migraine had 
anxiety alone, 3% had depression alone, and 19% had 
both anxiety and depression.7 The lower rate of anx-
iety vs depressive symptoms in our analysis may be 
attributed to our use of the GAD-7, which assesses 
symptoms of generalized anxiety disorder but not other 
anxiety disorders such as panic disorder. Thus, we may 
have underestimated the prevalence of anxiety symp-
toms in the CaMEO population. The AMPP Study10 
and the CaMEO Study used similar approaches to de-
fining migraine and assessing depression and anxiety, 
yet, the rates of depression and anxiety were lower in 
the AMPP Study population compared with the pres-
ent report.10 About 30% of respondents with CM were 
categorized as having depression (PHQ-9 score ≥10) 
in the AMPP Study compared with 57% in the cur-
rent analysis. In the AMPP Study, about 30% had a 
self-reported physician diagnosis of an anxiety disor-
der, whereas in this sample 48% were classified as pos-
itive for clinically relevant anxiety symptoms (GAD-7 
total score ≥10). The AMPP Study had a higher par-
ticipation rate than the CaMEO Study (65% vs 17%), 
and AMPP Study data were collected by mailed ques-
tionnaire in contrast with the Web survey used in the 
CAMEO Study.37 Perhaps these differences in popu-
lations and methodologies account for between-study 
differences.
In addition to the well-described comorbidity of 
migraine, anxiety, and depression, previous studies 
have provided further evidence that comorbid depres-
sion and/or anxiety significantly negatively influence 
QoL and increase the burden of migraine.16,17 For ex-
ample, in a small population of Korean patients with 
migraine, depression, and anxiety together were associ-
ated with a significant increase in headache frequency 
in comparison to patients with migraine without either 
comorbidity alone.38 In that same population, anxiety 
alone and anxiety plus depression were associated with 
more intense headache pain than was the absence of 
these comorbidities.38
People with migraine and comorbid anxiety and/or 
depression respond differently to acute and preventive 
migraine treatments than do those without anxiety or 
depression. The FRAMIG 3 Study observed that per-
ceived efficacy of and satisfaction with acute treatment 
of migraine were lower in people with anxiety alone or 
depression and anxiety together than in those with nei-
ther depression nor anxiety, indicating that acute treat-
ment may be suboptimal in this subset of the migraine 
population.7 In contrast, people with migraine and 
depression and/or anxiety may respond better to pre-
ventive treatment than those without either comorbid-
ity. An analysis of data from the Treatment of Severe 
Migraine trial (n = 177), reported greater reductions in 
migraine days and migraine-related disability with pre-
ventive treatment in participants with a mood and/or 
anxiety disorder diagnosis compared with those who 
had neither diagnosis.19
Total annual health-care expenses for patients with 
migraine and depression were found to be higher com-
pared with costs for patients with migraine without 
comorbid depression ($10,012 vs $4740; P < .001).15 In 
addition, patients with comorbid depression were more 
likely to use migraine prophylactic medication than pa-
tients with migraine alone (50.6% vs 37.3%, P < .001) 
and were also more likely to use health services (doc-
tor visits, prescriptions, emergency department visits, 
or hospital admissions) for any cause than were those 
with migraine alone. It is not possible to determine 
causation from these relationships, which may be influ-
enced by biases such as Berkson’s bias. The results of 
our study and previous studies support a need for fur-
ther investigations of the effect of depression and anx-
iety on migraine-related disability and QoL to improve 
treatment, mitigate disability, and optimize health-care 
resource utilization.
Clinical Implications.—Although this cross- 
sectional analysis does not support causal inferences, 
we show that at any headache frequency, levels of 
disability are greater in persons with migraine and 
depression or anxiety and particularly among those 
with both psychiatric comorbidities. Figure 4 suggests 
2 approaches to improving disability. One approach is 
to reduce headache-day frequency so that disability de-
clines with leftward movement along 1 of the curves. 
One trial found that beta-blocker, behavioral migraine 
treatment, or their combination (vs placebo) reduced 
headache disability to a greater extent in people with 
comorbid depression and/or anxiety disorders than 
in people without these comorbidities.19 A second 
approach is to address depression, anxiety, or both in 
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people with migraine and these comorbid disorders. 
Even if  the frequency of headache days remains stable, 
relief  of depression or anxiety could result in a down-
ward shifting of curves, resulting in decreased disabili-
ty at a particular level of headache frequency. Pain in-
tensity and disability are correlated but not in a direct 
linear fashion,39 further supporting the hypothesis that 
intervention in perception and coping skills such as 
those taught with cognitive behavioral therapy (CBT) 
may help reduce disability.40 These 2 approaches, 
reducing monthly headache days and reducing psychi-
atric comorbidities, provide alternative and perhaps 
complimentary approaches to reducing disability avail-
able for future testing.
Limitations.—Limitations of this present study in-
clude the self-reported nature of the data; clinically 
relevant depression and anxiety were determined by 
screening tests administered online and do not represent 
a diagnosis or examination by a health-care profession-
al. We used the validated sum scoring methods for the 
GAD-7 and the PHQ-9, which do not follow the DSM-
IV algorithm scoring approach which requires endorse-
ment of the first 2 hallmark symptoms of depression; 
however, they are validated scoring methods and espe-
cially helpful for assessing severity. Although it could 
be argued that the data are subject to reporting bias by 
individual respondents, as with migraine, there are no 
lab tests or markers for depression and anxiety. Clin-
ical diagnosis is determined through interview, where 
patients also self-report both migraine and psychiatric 
symptoms to assess criteria and assign diagnosis. In 
addition, strong agreement has been reported between 
Internet-based self-reported and proxy-reported data, 
supporting the validity of survey data.41 Furthermore, 
although the present screening tools have been validat-
ed for depression and anxiety,26,28 the GAD-7 assesses 
symptoms of generalized anxiety disorder only; there-
fore, results do not generalize to other anxiety disor-
ders such as panic disorder. Future studies of anxiety 
in people with migraine should consider inclusion of 
validated questionnaires that assess different anxiety 
features, such as the Beck Anxiety Inventory42 and the 
Anxiety Symptoms Questionnaire.43 Although our 
results are similar to those reported elsewhere, ob-
served discrepancies may result, including prevalence, 
in part, from differences in patient self-reporting and 
health-care professional diagnoses, the use of different 
assessment methodologies, and/or differences among 
populations. Given the observed bidirectionality be-
tween psychiatric comorbidities and migraine and the 
cross-sectional nature of this current analysis, causality 
cannot be determined. Furthermore, rate ratios must 
be interpreted with caution because data related to po-
tential confounding factors have not been collected or 
explored. Finally, because this is a subanalysis, the 
sample size was not predetermined to ensure sufficient 
study power to produce a statistically significant result. 
Nevertheless, our findings are consistent with those of 
other studies, as described above.
Unraveling the present effect on disability at a 
mechanistic level is challenging because of the com-
plex interactions of depression and anxiety symptoms 
comorbid with migraine and observed bidirectional 
associations. Many confounding factors could poten-
tially contribute independently to disability, limiting 
our ability to draw definitive conclusions regarding the 
effects of depression and anxiety on headache-related 
disability. Further investigations must be undertaken in 
a population with migraine and comorbid psychiatric 
disorders to confirm and further explore the findings 
of this analysis. Additional studies of the disability 
associated with other comorbid psychiatric disorders 
such as bipolar spectrum and personality disorders in 
people with migraine would also be of interest. A high 
proportion of people with recurrent depression have 
bipolar spectrum disorders and bipolar spectrum dis-
orders are associated with somatic symptoms includ-
ing headache.44,45 Assessing these associations is an 
important task for future research.
CONCLUSIONS
Compared with respondents without either de-
pression or anxiety, respondents with depression and 
anxiety reported higher levels of headache-related dis-
ability. The greatest level of headache-related disability 
occurred in respondents with both depression and anx-
iety. A significantly greater proportion of respondents 
with CM reported psychiatric comorbidities, consist-
ent with the greater overall burden associated with CM 
than EM. Moreover, headache-related disability in-
creased with headache-day frequency across the range 
of monthly headache days, suggesting a continuum 
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of disability. Additional longitudinal analyses of the 
CaMEO Study data may provide further information 
on relationships among headache characteristics, co-
morbidities, and disability. From a clinical treatment 
perspective, the results reinforce the importance of 
managing the total burden of migraine, including dis-
ability, QoL, and associated comorbidities.
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